Skip to main content

Table 1 Patients’ characteristics according to RRM1 expression

From: RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy

Features

N

RRM1 expression

λ2

p

Low (%)

High (%)

Unknown (%)

Gender

 Female

30

11 (17.2)

3 (17.6)

16 (19.8)

0.166

0.921

 Male

132

53 (82.8)

14 (82.4)

65 (80.2)

  

Age (years)

  ≤ 60

85

39 (60.2)

12 (70.6)

34 (42.0)

3.542

0.170

  > 60

77

25 (39.8)

5 (29.4)

47 (58.0)

  

Weight (Kg)

  ≤ 65

78

26 (40.6)

8 (47.1)

44 (56.4)

2.695

0.260

  > 65

84

38 (59.4)

9 (52.9)

37 (44.0)

  

ECOG Score

 0–1

157

62 (96.9)

17 (100.0)

78 (96.3)

0.645

0.724

 2

5

2 (3.1)

0

3 (3.7)

  

CUA/EAU risk group

 2

54

22 (34.4)

6 (35.3)

26 (32.1)

0.116

0.944

 3

108

42 (65.6)

11 (64.7)

55 (67.9)

  

Relapse

 Yes

23

3 (4.9)

5 (29.4)

15 (18.5)

9.223

0.010

 No

139

61 (95.1)

12 (70.6)

66 (81.5)

  
  1. p < 0.05 is set in boldface